Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Glenmark, Dr Reddy’s Launches Favipiravir For Indian Market

Pfizer, Novartis and Mylan Announce Further Measures To Tackle The Pandemic

Executive Summary

While Dr Reddy’s partners with Fujifilm Toyama for favipiravir for the Indian market, Pfizer and Gilead join together to increase the manufacturing and supply of investigational antiviral treatment remdesivir. Mylan donates a million dollars to Sesame Workshop to provide socio-emotional support to children and families to cope with the uncertainties caused by COVID-19, while Glenmark introduces a higher strength of Fabiflu for the Indian market.

You may also be interested in...



Aurobindo Announces Vaccine Partnership For India

Aurobindo has partnered with US based Covaxx for the first-ever peptide-based COVID-19 vaccine for the Indian market. While Dr Reddy’s has filed for favipiravir in Canada, Cipla has launched its second antigen detection test kit in India. And the Serum Institute of India will be providing Bangladesh with Oxford-AstraZeneca vaccine doses via Beximco

Sandoz Takes Zero-Profit Approach To COVID-19 In Africa

As Sandoz tries to assist African Union member states by selling its pandemic response portfolio medicines for zero profit, mAbxience has partnered with AstraZeneca to produce a vaccine. And CDMO Hovione has struck a deal with Ligand to boost manufacturing of Captisol, a critical ingredient for Gilead’s remdesivir.

India’s Saptagir Partners With Jubilant On Remdesivir

India’s Saptagir Laboratories has struck a deal with Jubilant Pharma to manufacture the ingredient for COVID-19 emergency treatment remdesivir. Meanwhile, following in the footsteps of Cipla, Hetero, Mylan and Zydus, Dr Reddy’s has launched its version of remdesivir for the Indian market under a licensing deal with Gilead.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel